« Return to News | Study Conduct

Initiative to double survival rate for pancreatic cancer calls for more clinical trial participants

Monday, January 9, 2012 09:17 AM

The Pancreatic Cancer Action Network is calling for increased participation in clinical trials as part of its initiative to double the survival rate of pancreatic cancer by 2020.

Currently only three FDA approved drugs to treat pancreatic adenocarcinoma, the most common type of pancreatic cancer, are available. Although many other clinical trials are planned or in process, participant numbers are low. The Pancreatic Cancer Action Network stresses that increased participation, and in turn increased clinical trials, are vital to meeting its 2020 goal.

The organization also encouraged patients with pancreatic cancer to consider clinical trials when exploring treatment options.

“Through participation in clinical trials, patients have access to cutting edge research and are taking an active role in advancing pancreatic cancer research. Clinical trials pave the way to therapeutic breakthroughs,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.